Carcinoma cancer
Pro Research Analysisby 
Searched over 200M research papers for "carcinoma cancer"
Consensus Meter
Carcinoma Cancer: An Overview
Hepatocellular Carcinoma: Prevalence, Risk Factors, and Treatment
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer globally and the third leading cause of cancer-related deaths. It primarily affects patients with cirrhosis, making regular surveillance with ultrasonography crucial for early diagnosis and treatment. Early-stage HCC can be treated with resection, liver transplantation, or ablation, achieving a 5-year survival rate of over 50%. Liver transplantation is particularly beneficial for patients who meet the Milano criteria, although donor shortages limit its applicability. For advanced cases, molecular-targeted therapies like sorafenib have shown survival benefits, highlighting the potential of these treatments in managing chemoresistant HCC .
Renal Cell Carcinoma: Subtypes and Advances in Treatment
Renal cell carcinoma (RCC) originates from the renal epithelium and accounts for over 90% of kidney cancers. Clear cell RCC (ccRCC) is the most common subtype and is associated with the highest mortality. Recent genomic studies have identified mutations in epigenetic regulatory genes, which have prognostic and therapeutic implications. While localized RCC can be managed surgically, metastatic RCC is resistant to conventional chemotherapy. However, targeted therapies, including VEGF inhibitors (sorafenib, sunitinib) and mTOR inhibitors (everolimus, temsirolimus), have significantly improved outcomes for metastatic RCC patients.
Basal Cell Carcinoma: Epidemiology and Clinical Features
Basal cell carcinoma (BCC) is the most common human cancer, with a rising incidence worldwide. It is associated with significant morbidity and healthcare costs. Advances in research have enhanced our understanding of BCC's epidemiology, clinical presentations, and pathogenesis. BCC typically presents as localized lesions that can be effectively treated with surgical excision or other localized therapies.
Ovarian Carcinomas: Distinct Types and Molecular Pathology
Ovarian carcinomas are the most lethal gynecological malignancies, divided into five main types based on histopathology and genetic alterations: high-grade serous, endometrioid, clear cell, mucinous, and low-grade serous carcinomas. These subtypes have distinct origins, genetic risk factors, and responses to chemotherapy. Recent studies suggest that many ovarian carcinomas may originate in the fallopian tubes or endometrium, rather than the ovaries themselves. Accurate histopathological diagnosis is critical for effective treatment.
Carcinosarcomas: Epithelial-Mesenchymal Transition and Treatment
Carcinosarcomas, often gynecologic in origin, are rare tumors that exemplify the epithelial-mesenchymal transition (EMT). This process involves the transformation of epithelial cells into mesenchymal cells, contributing to tumor progression and metastasis. Carcinosarcomas generally have a worse prognosis than carcinomas of the same site. Treatment typically follows protocols for carcinomas, but there is potential for therapies targeting EMT to improve outcomes.
Molecular Classification of Carcinomas
Recent advancements in molecular classification using gene expression signatures have enabled more precise identification of carcinoma origins. This approach involves large-scale RNA profiling and machine learning to classify tumors based on their gene expression patterns. Such molecular classification can predict the tissue origin of carcinomas with high accuracy, aiding in the development of targeted therapies.
Conclusion
Carcinoma encompasses a diverse group of cancers with varying origins, genetic profiles, and treatment responses. Advances in molecular biology and targeted therapies have significantly improved the management of several carcinoma types, including hepatocellular, renal cell, basal cell, ovarian, and carcinosarcomas. Continued research into the molecular mechanisms and treatment strategies for these cancers holds promise for further improving patient outcomes.
Sources and full results
Most relevant research papers on this topic